Redefining the real problem in psychedelic trials: Why fighting the Lessebo matters more than blinding integrity.
The International journal on drug policy July 8, 2026 Laetitia Vanderijst, Jean-Luc Faillie, Thibault Mura et al.
Imperfect blinding is not specific to psychedelic trials. In randomized trials, treatment allocation is frequently correctly guessed, yet blinding integrity is rarely assessed outside of psychedelic research and is generally not considered a barrier in regulatory evaluation. The intense debate in psychedelics may reflect a broader double standard affecting mental health research, when...